Management of cardiovascular risk in the perimenopausal women: A consensus statement of European cardiologists and gynecologists

Climacteric

Volumn 10, Issue 6, 2007, Pages 508-526

  Collins, P ^a   Rosano, G ^b   Casey, C ^c   Daly, C ^a   Gambacciani, M ^d   Hadji, P ^e   Kaaja, R ^f   Mikkola, T ^f   Palacios, S ^g   Preston, R ^h   Simon, T ⁱ   Stevenson, J ^a   Stramba Badiale, M ^j  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b Centre for Clinical and Basic Research   (Italy)

^c ST JOHN'S HOSPITAL   (Ireland)

^d UNIVERSITY OF PISA   (Italy)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j ISTITUTO AUXOLOGICO ITALIANO   (Italy)

more..

Author keywords

Cardiology; Cardiovascular Prevention; Cardiovascular Risk; Gynecology; Hormones; Hypertension; Menopause; Metabolic Syndrome

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DYDROGESTERONE PLUS ESTRADIOL; ENALAPRIL; EPLERENONE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE; ESTRADIOL VALERATE PLUS NORGESTREL; ESTRIOL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOFLAVONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PERINDOPRIL; PIPERAZINE ESTRONE SULFATE; SPIRONOLACTONE; TRIACYLGLYCEROL; UNINDEXED DRUG;

AGING; ANXIETY; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; BREAST CANCER; CALORIC INTAKE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; DEPRESSION; DIABETES CONTROL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; GLUCOSE INTOLERANCE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; NIGHT SWEAT; OBESITY; ORAL CONTRACEPTION; PHYSICAL ACTIVITY; PHYSICIAN ATTITUDE; POSTMENOPAUSE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; THROMBOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL; VASOMOTOR DISORDER;

ADULT; ATHEROSCLEROSIS; CARDIOLOGY; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; EUROPE; FEMALE; GYNECOLOGY; HUMANS; HYPERTENSION; MIDDLE AGED; PERIMENOPAUSE; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY PREVENTION; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 36749054787     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701755213     Document Type: Review

References (135)

1. Mosca L, Jones WK, King KB, Ouyang P, Redberg RF, Hill MN. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. American Heart Association Women's Heart Disease and Stroke Campaign Task Force. Arch Fam Med 2000;9:506-15
2. Weisz D, Gusmano MK, Rodwin VG. Gender and the treatment of heart disease in older persons in the United States, France, and England: a comparative, population-based view of a clinical phenomenon. Gend Med 2004;1:29-40
3. Peterson S, Peto V, Rayner M, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics, 2nd edn. London: British Heart Foundation, 2005
4. Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006;27:994-1005
5. Benagiano G, Farris M. Why a consensus conference on hormone replacement therapy and the cardiovascular system? Maturitas 2004;47:245-53
6. Naftolin F, Schneider HP, Sturdee DW, et al.; Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:333-7
7. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions. J Am Coll Cardiol 2006;47:1741-53
8. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004;109:1101-7
9. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-57
10. Simon T, Mary-Krause M, Cambou JP, et al.; USIC Investigators. Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: increased early risk in younger women: results from the French nation-wide USIC registries. Eur Heart J 2006;27:1282-8
11. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001;103:375-80
12. Reunanen A, Suhonen O, Aromaa A, Knekt P, Pyorala K. Incidence of different manifestations of coronary heart disease in middle-aged Finnish men and women. Acta Med Scand 1985;218:19-26
13. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-90
14. Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. JAMA 2005;293:477-84
15. Senoz S, Direm B, Gulekli B, Gokmen O. Estrogen deprivation, rather than age, is responsible for the poor lipid profile and carbohydrate metabolism in women. Maturitas 1996;25:107-14
16. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
17. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
18. Women and smoking: a report of the Surgeon General. Executive summary. MMWR Recomm Rep 2002;51:i-iv
19. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998;316:1043-7
20. Castelli WP. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. Am J Obstet Gynecol 1999;180:S349-56
21. Goldbaum GM, Kendrick JS, Hogelin GC, Gentry EM. The relative impact of smoking and oral contraceptive use on women in the United States. JAMA 1987;258:1339-42
22. Rangemark C, Benthin G, Granstrom EF, Persson L, Winell S, Wennmalm A. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation 1992;86:1495-500
23. Dotevall A, Rangeark C, Erikssib E, Kutti J, Wadenvik H, Wennmalm A. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. Thromb Haemost 1992;68:583-8
24. Kalra VK, Ying Y, Deemer K, Natarajan R, Nadler JL, Coates TD. Mechanism of cigarette smoke condensate induced adhesion of human monocytes in cultured endothelial cells. J Cell Physiol 1994;160:154-62
25. Fruzzetti F, Ricci C, Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994;49:579-92
26. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202-9
27. Keeling D. Combined oral contraceptives and the risk of myocardial infarction. Ann Med 2003;35:413-8
28. Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives, an updated analysis of a cohort study. Br J Obstet Gynaecol 1998;105:890-6
29. Jonsdottir LS, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 2002;9:67-76
30. De Backer G, Ambrosioni E, Borch-Johnsen K, et al.; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10
31. Barter P, Kastelein J, Nunn A, Hobbs R; Future Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003;168:195-211
32. Forouhi NG, Merrick D, Goyder E, et al. Diabetes prevalence in England, 2001 - estimates from an epidemiological model. Diabet Med 2006;23:189-97
33. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288-99
34. Lobner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 2006;55:792-7
35. World Health Organization. Prevention of diabetes. Report of the WHO study group. Technical series 844. 2004. Geneva: WHO
36. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96
37. Hasdai D, Porter A, Rosengren A, Behar S, Boyko V, Battler A. Effect of gender on outcomes of acute coronary syndromes. Am J Cardiol 2003;91:1466-9
38. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001
39. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002;162:1737-45
40. Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. Diabetes Care 1991;14:537-43
41. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73-8
42. Pyorala K, Lehto S, De Bacquer D, et al.; EUROASPIRE I Group; EUROASPIRE II Group. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004;47:1257-65
43. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. Climacteric 2004;7:375-89
44. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004;351:2694-703
45. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80
46. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8
47. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-3421
48. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19(Suppl A):A2-11
49. Kaaja RJ, Poyhonen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006;24:131-41
50. Kaaja R, Laivuori H, Pulkki P, Tikkanen MJ, Hiilesmaa V, Ylikorkala O. Is there any link between insulin resistance and inflammation in established preeclampsia? Metabolism 2004;53:1433-5
51. Haukkamaa L, Salminen M, Laivuori H, Leinonen H, Hiilesmaa V, Kaaja R. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol 2004;93:805-8
52. Bernstein MS, Morabia A, Sloutkis D. Definition and prevalence of sedentarism in an urban population. Am J Public Health 1999;89:862-7
53. Castelo-Branco C, Blumel JE, Roncagliolo ME, et al. Age, menopause and hormone replacement therapy influences on cardiovascular risk factors in a cohort of middle-aged Chilean women. Maturitas 2003;45:205-12
54. Lukkarinen H, Hentinen M. Assessment of quality of life with the Nottingham Health Profile among women with coronary heart disease. Heart Lung 1998;27:189-99
55. Barford A, Dorling D, Davey-Smith G, Shaw M. Life expectancy: women now on top everywhere. BMJ 2006;332:808
56. United Nations. Population aging. www.un.org/esa/population/publications/ aging99 (1999)
57. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 2005;14:19-29
58. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-5
59. Buckler H. The menopause transition: endocrine changes and clinical symptoms. J Br Menopause Soc 2005;11:61-5
60. Zichella L. Clinical management of the menopausal woman. Int J Fertil Menopausal Stud 1993;38(Suppl 1):15-22
61. Baum LW. Sex, hormones, and Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2005;60:736-43
62. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-80
63. Kronenberg F. Hot flushes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319-36
64. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-18
65. Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004;7:189-96
66. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-71
67. Vanwesenbeeck I, Vennix P, van de Wiel H. 'Menopausal symptoms': associations with menopausal status and psychosocial factors. J Psychosom Obstet Gynaecol 2001;22:149-58
68. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy - a placebo-controlled study. Int J Fertil Menopausal Stud 1995;40:73-8
69. Col NF, Weber G, Stiggelbout A, Chuo J, D'Agostino R, Corso P. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med 2004;164:1634-40
70. Badia X, Diez-Perez A, Lahoz R, Lizan L, Nogues X, Iborra J. The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis. Health Qual Life Outcomes 2004;2:41
71. Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
72. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-52
73. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001;39:125-32
74. Ferrannini E. Physiological and metabolic consequences of obesity. Metabolism 1995;44:15-7
75. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:698-9
76. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005;28:385-407
77. Lindheim SR, Buchanan TA, Duffy DM, et al. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Investig 1994;1:150-4
78. Samsioe G. HRT and cardiovascular disease. Ann N Y Aad Sci 2003;997:358-72
79. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sándwich L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005;52:111-8
80. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53
81. Kuhl H. Breast cancer risk in the WHI study: the problem of obesity. Maturitas 2005;51:83-97
82. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
83. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-32
84. Sullivan JM, El Zeky F, Vander ZR, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847-50
85. Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D. Hormone therapy and inhospital survival after myocardial infarction in postmenopausal women. Circulation 2001;104:2300-4
86. Dias AR Jr, Melo RN, Gebara OC, et al. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric 2005;8:63-70
87. Clarkson TB. Progestogens and cardiovascular disease. A critical review. J Reprod Med 1999;44:180-4
88. Manson JE, Hsia J, Johnson KC, et al.; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
89. Anderson GL, Limacher M, Assaf AR, et al.; Women's Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
90. Hsia J, Langer RD, Manson JE, et al.; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65
91. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44
92. Cushman M, Kuller LH, Prentice R, et al.; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
93. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al.; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84
94. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
95. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
96. Bartys S, Baker D, Lewis P, Middleton E. Inequity in recording of risk in a local population-based screening programme for cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2005;12:63-7
97. O'Brien E, Asmar R, Beilin L, et al.; European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005;23:697-701
98. Conroy RM, Pyorala K, Fitzgerald AP, et al.; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
99. Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003;327:1264-8
100. McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognositic significance of stable angina pectoris among woman and men. JAMA 2006;295:1404-11
101. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J.Hypertens 2003;21:1011-53
102. Hersberger M, von Eckardstein A. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport. Handb Exp Pharmacol 2005;170:537-61
103. Marshall T. Coronary heart disease prevention: insights from modeling incremental cost effectiveness. BMJ 2003;327:1264
104. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206
105. Messerli F, White WB, Staessen JA. If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials. J Am Coll Cardiol 2002;40:2201-3
106. Coleman AJ, Steel SD, Ashworth M, Vowler SL, Shennan A. Accuracy of the pressure scale of sphygmomanometers in clinical use within primary care. Blood Press Monit 2005;10:181-8
107. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens 1994;12(Suppl):S5-14
108. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7
109. Svetkey LP. Management of prehypertension. Hypertension 2005;45:1056-61
110. Julius S, Nesbitt SD, Egan BM, et al.; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685-97
111. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004;43:918-23
112. Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension 2005;46:185-93
113. Hall JE, Guyton AC, Coleman TG, Mizelle HL, Woods LL. Regulation of arterial pressure: role of pressure natriuresis and diuresis. Fed Proc 1986;45:2897-903
114. Basso N, Paglia N, Stella I, et al. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 2005;128:247-52
115. Duprez D, De Buyzere M, Rietzschel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2000;2:327-34
116. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004;61:663-70
117. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
118. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
119. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
120. Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002;15:816-22
121. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797-804
122. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-84
123. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716-27
124. Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas 2004;49:189-203
125. Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
126. Holcomb SS. Selection of antihypertensive agents in patients with risk for diabetes. Curr Hypertens Rep 2005;7:461-5
127. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004;43:918-23
128. Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens 2006;20:101-8
129. Lee YJ, Chiang YF, Tsai JC. Severe nonproductive cough and cough-induced stress urinary incontinence in diabetic postmenopausal women treated with ACE inhibitor. Diabetes Care 2000;23:427-8
130. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-41
131. Daly C, Clemens F, Lopez Sendon JL, et al.; Euro Heart Survey Investigators. Gender differences in the management and clinical outcome of stable angina. Circulation 2006;113:490-8
132. Hayward CS, Kelly RP, Collins P. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 2000;46:28-49
133. Stramba-Badiale M, Priori SG. Gender-specific prescription for cardiovascular diseases? Eur Heart J 2005;26:1571-2
134. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11
135. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific metaanalysis of randomized controlled trials. JAMA 2006;295:306-13